Vertex Says Hepatitis Study Positive
January 10, 2006
On Monday, biotech firm Vertex Pharmaceuticals Inc. said an early study of its experimental hepatitis C drug VX-950 and pegylated interferon found the combination therapy was more effective at reducing blood levels of the virus than either treatment alone. In the 14-day trial of eight patients, the combination treatment was also well-tolerated. In the next few months, Vertex plans to start a mid-stage study involving more than 200 patients. Depending on results from that study, a Phase III trial could get underway in 2007, the company said.
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.